Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 22:07:30 Source:travelViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Arrest Lord Mountbatten's self
Next:Jodie Turner
You may also like
- China's first intelligent offshore drilling platform installed
- China sees smooth road traffic on first day of holiday
- 39 killed in deadly building fire in Jiangxi
- Excitement builds in Leverkusen ahead of expected Bundesliga title win
- Arrest Lord Mountbatten's self
- China releases list of first batch of pilot cities seeking to peak carbon dioxide emissions
- China to further enhance medical treatment for critical pregnant women
- Beijing, Hebei province brace for forecast snow
- Rishi Sunak to apologise for worst treatment disaster in NHS history